Detail akcie BioNTech Sp ADS online

Business Summary: BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, BioNTech SE - ADR revenues increased 26% to EUR1.96B. Net loss decreased 10% to EUR831.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects inventory write-downs decrease of 26% to EUR76.1M (expense), Other Operating Income - Balancing value increase from EUR10.9M to EUR37.2M (income).